Theratechnologies Inc.TSX: TH

Theratechnologies launches Phase III clinical trial for TH9507 (ThGRF) treating HIV-associated lipodystrophy

· Issued by Theratechnologies Inc. via CNW
MONTREAL, July 5 /CNW Telbec/ - Theratechnologies (TSX: TH) announced
today that on June 30 a patient in Atlanta, Georgia, became the first to begin
treatment in the Phase III clinical trial testing Theratechnologies' TH9507
(ThGRF) compound in HIV associated lipodystrophy, a condition that affects
many patients undergoing HIV antiretroviral therapy.
"I am pleased to report that the Phase III study got off the ground on
June 30, in keeping with our mid-year objective," noted Yves Rosconi,
President and Chief Executive Officer of Theratechnologies. "Including the
Atlanta site, we now have 6 of the projected 35 sites actively recruiting
patients and we are working hard towards opening the remaining 29 sites and
recruiting the 400 patients we need to complete the study. Our goal is to
announce results in the second half of 2006," Mr. Rosconi added.
HIV-associated lipodystrophy is characterized by changes in distribution
of adipose tissue (fat-containing tissue), dyslipidemia and glucose
intolerance. The changes in fat distribution include visceral adipose tissue
(VAT) accumulation and/or the loss of subcutaneous fat, generally in the limbs
and facial area. The multi-center, randomized, double-blind, placebo-
controlled Phase III clinical trial is investigating the safety and efficacy
of TH9507 in reducing excess VAT in approximately 400 patients by
administering 2 mg daily for a period of 26 weeks. There will also be an
extension phase of the study lasting an additional 26 weeks to assess      
long-term safety and the effects of discontinuing treatment.
A Canadian component of the study is being prepared and will be led by
Dr. Julian Falutz, Director of the HIV Metabolic Clinic at the Montreal
General Hospital and Assistant Professor at the McGill University Medical
School. Dr. Falutz has been treating HIV patients since the beginning of the
epidemic in the early 1980s. "With combination antiretroviral therapies now
available, the prognosis and quality of life for treated HIV patients have
improved dramatically," Dr. Falutz stated. "However, toxicity may be
significant and treatment-limiting at times. One of the most important side
effects is HIV-associated lipodystrophy, with its potential to cause important
body-shape changes as well as lipid and glucose abnormalities," he added.
Dr. Steven Grinspoon, Director, Program in Nutritional Metabolism at
Massachusetts General Hospital, and Associate Professor of Medicine at Harvard
University is the Lead Investigator for the clinical study in the United
States. Dr. Grinspoon stresses the importance of finding an effective
treatment for HIV-associated lipodystrophy patients. "This condition increases
their risk of developing cardiovascular disease and type 2 diabetes, and
what's also worrisome, the body abnormalities related to lipodystrophy can
stigmatize patients and discourage compliance with their HIV regimens,"
Dr. Grinspoon explained.
Dr. Melanie Thompson, principal investigator of the AIDS Research
Consortium of Atlanta, enrolled the first patient on the study and was an
investigator on the Phase II clinical trial of TH9507. Dr Thompson is former
Chair of the U.S. Office of AIDS Research Therapeutics Research Working group
and serves on the International AIDS Society-USA Antiretroviral Treatment
Guidelines Panel. "We are truly excited to be initiating this study because of
the need for treatment for lipodystrophy. This disorder is a source of severe
stress for patients and also may be associated with diabetes, high cholesterol
and other factors for cardiovascular disease," Dr. Thompson said. "There has
been a lot of interest in this particular drug candidate because Phase II
clinical trial results indicate that TH9507 may reduce VAT effectively and
safely, even in patients with impaired glucose tolerance," she added.
Mr. Rosconi believes that a specialized indication like HIV-associated
lipodystrophy is an ideal entry point to bring TH9507 to the market. "Our
market studies indicate that among the 1.1 million HIV-positive patients in
North America and Europe, nearly 200,000 suffer from HIV-associated
lipodystrophy with excess VAT accumulation", Mr. Rosconi said. "It's a
potential market of several hundred million dollars, and yet, the scale of the
Phase III clinical trials and the relatively small number of doctors we will
need to speak to about prescribing TH9507 make this a manageable project for a
company our size," he concluded.

About TH9507

TH9507 is a stabilized analogue of the growth hormone-releasing factor
(GRF) that induces the production and secretion of growth hormone in a
specific, physiological, controlled and pulsatile fashion. This property makes
it a strong candidate as a potential treatment for many diseases characterized
by a reduction in growth hormone secretion.

About Theratechnologies

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company
engaged in the discovery and development of therapeutic peptides in the field
of endocrinology and metabolism. The Company uses proprietary discovery
technologies to expand its product portfolio. The most advanced clinical
program (Phase III) targets HIV-associated lipodystrophy with its lead
compound, TH9507 (ThGRF). The Company is investigating other potential
indications for TH9507 and it also has an interesting product pipeline
targeting type 2 diabetes.

This press release contains forward-looking statements regarding the
clinical development of TH9507 and its future commercialization in the
indication described above. Such statements inherently involve numerous risks
and uncertainties, including the availability of funds and resources, the
success and timely completion of clinical trials and the granting of the
necessary authorizations. Actual future results may differ materially from the
anticipated results. Investors are cautioned against placing undue importance
on forward-looking information contained herein and should consult the
Company's 2004 Annual Report, which contains a more exhaustive analysis of
risks and uncertainties connected to the businesses of the Company.

Theratechnologies Inc. on 6ix

Story so far

Earlier from Theratechnologies

Later from Theratechnologies

All Theratechnologies news releases